461 related articles for article (PubMed ID: 29170252)
1. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
Lengline E; Drenou B; Peterlin P; Tournilhac O; Abraham J; Berceanu A; Dupriez B; Guillerm G; Raffoux E; de Fontbrune FS; Ades L; Balsat M; Chaoui D; Coppo P; Corm S; Leblanc T; Maillard N; Terriou L; Socié G; de Latour RP
Haematologica; 2018 Feb; 103(2):212-220. PubMed ID: 29170252
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
[No Abstract] [Full Text] [Related]
3. Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Olnes MJ; Scheinberg P; Calvo KR; Desmond R; Tang Y; Dumitriu B; Parikh AR; Soto S; Biancotto A; Feng X; Lozier J; Wu CO; Young NS; Dunbar CE
N Engl J Med; 2012 Jul; 367(1):11-9. PubMed ID: 22762314
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
5. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S
Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; Kulasekararaj A; Iacobelli S; Terwel SR; Cook R; Griffin M; Halkes CJM; Recher C; Barraco F; Forcade E; Vallejo JC; Drexler B; Mear JB; Smith AE; Angelucci E; Raymakers RAP; de Groot MR; Daguindau E; Nur E; Barcellini W; Russell NH; Terriou L; Iori AP; La Rocca U; Sureda A; Sánchez-Ortega I; Xicoy B; Jarque I; Cavenagh J; Sicre de Fontbrune F; Marotta S; Munir T; Tjon JML; Tavitian S; Praire A; Clement L; Rabian F; Marano L; Hill A; Palmisani E; Muus P; Cacace F; Frieri C; van Lint MT; Passweg JR; Marsh JCW; Socié G; Mufti GJ; Dufour C; Risitano AM;
N Engl J Med; 2022 Jan; 386(1):11-23. PubMed ID: 34986284
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
[TBL] [Abstract][Full Text] [Related]
8. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):450-456. PubMed ID: 30504345
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag for the treatment of aplastic anemia: current perspectives.
Lum SH; Grainger JD
Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances and Long-Term Results of Medical Treatment of Acquired Aplastic Anemia: Are Patients Cured?
Scheinberg P
Hematol Oncol Clin North Am; 2018 Aug; 32(4):609-618. PubMed ID: 30047414
[TBL] [Abstract][Full Text] [Related]
11. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
Geng W; Kearney S; Nelson S
Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
Hong Y; Li X; Wan B; Li N; Chen Y
Clin Drug Investig; 2019 Feb; 39(2):141-156. PubMed ID: 30406906
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of eltrombopag in aplastic anemia: A multi-center survey in China].
Yang WR; Han B; Chang H; Wu BY; Meng FK; Ji DX; Li YM; Zheng ZJ; Fei Y; Shen JP; Hu P; Ding XQ; Zhang P; Wang YQ; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):890-895. PubMed ID: 33333690
[No Abstract] [Full Text] [Related]
14. Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
Martynova A; Chiu V; Mert M; Hermel D; Weitz IC
Ann Hematol; 2021 Apr; 100(4):933-939. PubMed ID: 33420879
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
Desmond R; Townsley DM; Dumitriu B; Olnes MJ; Scheinberg P; Bevans M; Parikh AR; Broder K; Calvo KR; Wu CO; Young NS; Dunbar CE
Blood; 2014 Mar; 123(12):1818-25. PubMed ID: 24345753
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag in children with severe aplastic anemia.
Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M
Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag is effective in patients with relapse/refractory aplastic anemia-report from a single center in China.
Ruan J; Zuo W; Chen M; Yang C; Han B
Ann Hematol; 2020 Dec; 99(12):2755-2761. PubMed ID: 32944791
[TBL] [Abstract][Full Text] [Related]
18. Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.
Peffault de Latour R; Huynh L; Ivanova JI; Totev T; Bilginsoy M; Antin J; Roy A; Duh MS
Ann Hematol; 2020 Apr; 99(4):743-752. PubMed ID: 32065291
[TBL] [Abstract][Full Text] [Related]
19. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Blood Adv; 2018 Nov; 2(21):3054-3062. PubMed ID: 30425070
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of the safety and efficacy of anti-thymocyte globulin combined with eltrombopag in the treatment of severe aplastic anemia.
Zhang J; Wu Y; Liu J; Han S; Chen L; Wang H; Peng Y
Ann Palliat Med; 2021 May; 10(5):5549-5560. PubMed ID: 34107711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
